Fairvalue-Calculator Fairvalue-Calculator
EN DE

Monopar Therapeutics Inc (MNPR) Fair Value & Analysis

Healthcare · US · Market cap $452M

Price$81.77
Fair Value$92.58
Upside+13.2%
Quality95/100
Evidence: Low Range $69.44 – $115.73

Fair value as of: Jun 24, 2026

Analysis

Monopar Therapeutics Inc (MNPR) currently trades at $81.77, while our model-based Fair Value estimate is $92.58 — implying the stock looks roughly 13.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Monopar Therapeutics Inc (MNPR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $92.58 versus a price of $81.77 — about +13% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MNPR?
Our 21-model fair value for Monopar Therapeutics Inc is $92.58 (as of Jun 24, 2026), built from audited fundamentals. The current price is $81.77.
What is the quality score of MNPR?
Monopar Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.